Earnings
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.
With this new collaboration, Astellas will take advantage of Dynos’ next-gen AAV vectors to deliver its gene therapy.
The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.
Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
Based on BridgeBio’s current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.
PRESS RELEASES